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Foreword
The purpose of the MYEFO report is to provide updated information to allow the 
assessment of the Government’s fiscal performance against the fiscal strategy set out in 
the current Budget Papers.  
The Treasurer must publicly release and table a Mid-year Economic and Fiscal Outlook 
(MYEFO) report by the end of January in each year, or within 6 months after the last 
budget, whichever is later. Typically, the MYEFO is released in November each year. This 
year it was released on November 2.
Over the past 12 months the global economic conditions have seriously impacted the 
fiscal outlook so this year the MYEFO was anxiously anticipated.
Angela Beaton
Lesley Russell
1Introduction
The Charter of Budget Honesty Act 1998 requires the Treasurer to publicly release and table a Mid-
year Economic and Fiscal Outlook (MYEFO) report by the end of January in each year, or within 6 
months after the last budget, whichever is later. Typically, MYEFO is released in November each 
year. This year it was released on November 2.
The purpose of the MYEFO report is to provide updated information to allow the assessment 
of the Government’s fiscal performance against the fiscal strategy set out in the current Budget 
Papers. Over the past 12 months the global economic conditions have seriously impacted the fiscal 
outlook so this year the MYEFO was anxiously anticipated.
Overview
While the Australian economy has performed better than expected, it is likely to remain below 
capacity for some time. The 2009-10 Budget projected an underlying cash deficit of $57.6 billion 
(4.9 per cent of GDP). The revised forecast underlying cash deficit for 2009-10 is $57.7 billion (4.7 
per cent of GDP), essentially unchanged from the May forecast.
The Budget deficit is an inevitable consequence of the global recession, which has resulted in 
downward revisions to revenue of around $210 billion since the 2008-09 Budget.
Policy decisions since the 2009-10 Budget have increased estimated expenses by $49 million in 
2009-10, but have reduced expenses by $2.1 billion over the forward estimates. 
Parameter and other variations since Budget have resulted in an increase in expenses of $1.9 
billion in 2009-10 (and $9.7 billion across the forward estimates).
The Government has invested $22 billion to improve infrastructure, of which, $3.2 billion was 
invested in health and hospital infrastructure. The Government will also provide $4.2 million 
over four years to fund a business case (to be completed early 2010) for establishing a national 
individual electronic health record system. 
2009-10 2010-11 2011-12 2012-13
Budget MYEFO Budget MYEFO Budget MYEFO Budget MYEFO
Commonwealth health 
budget ($m)
51,223 52,355 53,201 53,933 55,619 56,611 57,628 59,482
Table 1: Changes in Commonwealth Health Budget 2009-10 to 2012-13 since 2009-10 Budget
Health Measures Which Have Affected 
Budget Forecast
Overall, the MYEFO shows that policy decisions since the 2009-10 Budget have increased estimated 
expenses by $49 million in 2009-10, but have reduced expenses by $2.1 billion over the forward 
estimates (Table 1).  While a number of expense measures were listed, no major health policy 
decisions affecting expenditure were discussed.
2Parameter and other variations since Budget have resulted in an increase in health expenses of 
$1.9 billion in 2009-10 (and $9.7 billion across the forward estimates) reflecting:
•	 A $276 million ($1.1 billion over four years) increase in Private Health Insurance Rebate 
expenses primarily reflecting higher than expected take-up of private health insurance1; 
•	 A $266 million ($1.4 billion over four years) increase in forecast Medicare expenses largely 
reflecting higher than anticipated spending on GP consultations and the implementation of a 
new forecasting method2; 
•	 A $248 million increase in forecast expenses for the Chronic Disease Dental Scheme (CDDS) 
reflecting higher than anticipated expenditure for the period 1 July to 31 December 2009 
and the continuation of this scheme until 31 March 2010. The Government announced this 
scheme would cease in the 2008-09 Budget; however, the determination to cease the CDDS 
was disallowed by Parliament. Cessation  of the CDDS remains the Government’s policy; and 
•	 A $221 million ($1.8 billion over four years) increase in pharmaceutical and pharmaceutical 
services expenses to reflect increased demand for some drug groups which is expected to be 
sustained over the forward estimates period. 
The MYEFO includes two savings measures for health: 
•	 the creation of three new ‘therapeutic groups’ under the PBS - under which the 
Government will pay the same amount for medicines that deliver a similar health outcome 
(because the price at which the Government subsidises the cheapest medicine in the group 
are used as the basis for pricing the other medicines in that group). The new therapeutic 
groups, being created on the advice of the independent Pharmaceutical Benefits Advisory 
Council (PBAC), will result in a saving to the PBS of $48.2 million over the next four years. 
Changes in the price paid by the Government for these medications will not affect the majority 
of patients as their prescriber will choose the cheaper alternative medicine; and
•	 promoting the better use of selected spinal X-ray items on the Medicare Benefits 
Schedule, by encouraging practitioners to request region-specific X-rays for particular clinical 
indications and limit requesting rights for allied health practitioners in relation to three and 
four region spinal X-rays to one per patient per calendar year. This measure, which will also 
reduce the risk of unnecessary patient exposure to radiation, will result in a saving to the 
Medicare Benefits Schedule of $17.1m over the next four years. 
The only major policy decision affecting revenue in the health portfolio in the MYEFO in 2009-10 
was the modification to the 2009-10 Budget measures modifying the Pharmaceutical Benefits 
Scheme  viz. chemotherapy drugs (deferred implementation); listing of Revlimid® (lenalidomide); 
and minor new listings (figures were not provided, listed as not for publication).
However, a number of other budget measures have not yet been enacted, were significantly 
delayed, or have been deferred, which is likely to affect revenue/savings:
•	 Customs Tariff Amendment to increase the customs duty rate applying to certain alcoholic 
beverages (‘alcopops’) – DELAYED; passed by Senate, August 2009.
1  Despite these proposed changes, there was a $276 million ($1.1 billion over four years) increase in Private Health Insurance 
Rebate expenses, as discussed earlier, primarily reflecting higher than expected take-up of private health insurance.  The MYEFO 
projects continued growth in expenditure on the PHI rebate due to the continued growth in private health insurance membership.
2  The projected increase in Medicare costs is also likely to reflect continued blow-outs in the cost of the Better Access to 
Psychiatrists, Psychologists and GPs through the Medicare Benefits Schedule (MBS) program.  Please refer to ‘Trends affecting future 
health expenditure and impact on consumers’ in this document for a further explanation.
3•	 Responsible Economic Management — Chemotherapy Drugs — more efficient arrangements 
budget measure3 – DEFERRED.
•	 Withdrawal of the Medicare Chronic Disease Dental Scheme (CDDS) in favour of the 
Commonwealth Dental Health Program – DELAYED.
•	 Package of three bills to effect three private health insurance tiers (– DELAYED; re-introduced 
to Senate November 2009):
•	 Fairer Private Health Insurance Incentives Bill 2009 - The bill amends the Income 
Tax Assessment Act 1936 , Income Tax Assessment Act 1997 , Private Health 
Insurance Act 2007 , Taxation Administration Act 1953 and Taxation (Interest on 
Overpayments and Early Payments) Act 1983 to reduce the amount of private health 
insurance rebate (PHI rebate) eligible taxpayers with complying private health insurance 
are entitled to when their income for surcharge purposes is above the relevant Medicare 
levy surcharge (MLS) threshold.
•	 Fairer Private Health Insurance Incentives (Medicare Levy Surcharge) Bill 2009 - 
The bill amends the Medicare Levy Act 1986 to increase the rate of MLS for certain 
taxpayers who do not have complying health insurance and whose income for surcharge 
purposes is above the relevant MLS threshold.
•	 Fairer Private Health Insurance Incentives (Medicare Levy Surcharge—Fringe 
Benefits) Bill 2009 - The bill amends the A New Tax System (Medicare Levy Surcharge 
- Fringe Benefits) Act 1999 to increase the rate of MLS for taxpayers who do not have 
complying health insurance and whose income (including reportable fringe benefits) for 
surcharge purposes is above the relevant MLS threshold.
Specific Purpose and National Partnership 
Payments
Payments for specific purposes have been rationalized to five, including one Specific Purpose 
Payment (SPP) for health care.  National Partnership Payments (NPPs) will be used to facilitate 
reforms, support specific projects and reward the achievement of reform-based performance 
benchmarks. Existing payments for specific purposes and election commitments have become 
National Partnership project payments. They support national objectives or provide a financial 
contribution to the States to deliver specific projects.   
Each National SPP, including for health, is associated with a National Agreement that contains 
the objectives, outcomes, outputs and performance indicators, and clarifies the roles and 
responsibilities that will guide the Commonwealth and States in the delivery of services across the 
relevant sectors.
Implementation plans for some, but not all, of the National Partnerships for Health are available 
at: http://www.federalfinancialrelations.gov.au/content/national_partnership_agreements/health.
aspx 
3 The Government will defer the implementation of this Budget measure that, when implemented, will fund chemotherapy drugs 
listed on the PBS and under the Chemotherapy Pharmaceuticals Access Program according to the amount of active ingredient 
used, rather than the number of vials used. The deferral will allow further consultation with industry stakeholders to address 
implementation issues. The deferral will reduce savings to the PBS and RPBS Scheme by $36.3 million in 2009-10. 
4Of the $335.47 million for facilitation payments, and $307.47 million for reward payments (as 
outlined in the National Partnership Agreement on Preventive Health), it is estimated that as little 
as $4.1 million will be distributed to states in 2009-10.
Ministerial Council for Federal Financial Relations: Performance 
reporting for national agreements
The COAG Reform Council will be the independent assessor of whether pre-determined 
milestones and performance benchmarks have been achieved before an incentive payment to 
reward nationally significant reforms or service delivery improvements under a National Partnership 
reward payment is made. The final decision on payments will be made by the Commonwealth. To 
assist the COAG Reform Council, the agreements underpinning each National Partnership reward 
payment will clearly set out the milestones and performance benchmarks that must be achieved 
for each jurisdiction to be eligible for a payment.
Available at: http://www.federalfinancialrelations.gov.au/content/performance_reporting.aspx
Trends affecting future health expenditure 
and impact on consumers
Medicare Benefits Scheme
The projected increase in Medicare costs is likely to in part reflect continued blow-outs in the 
cost of the Better Access to Psychiatrists, Psychologists and GPs through the Medicare Benefits 
Schedule (MBS) program. An analysis of data from 2006 to 2009 shows the total cost of the Better 
Access program to June 2009 is $841.2 million.  On this basis, the total cost of this program over 
the 4 years since its introduction is predicted to be around $1.4 billion.
The rapid rate of increase in the uptake of all services continues, including out-patient services 
(Table 2), with the exception of GP-provided Focused Psychological Strategies services which are 
constant, perhaps even declining slightly.  
In 2007-08, a maximum of 664,419 people had a GP management plan.  These people received a 
total of 2,518,759 mental health services from GPs, psychologists, social workers and occupational 
therapists – an average of 3.8 services/person.  
In 2008-09, a maximum of 821,925 people had a GP management plan.  These people received a 
total of 3,389,243 mental health services from GPs, psychologists, social workers and occupational 
therapists – an average of 4.1 services/person.  The number of plans being reviewed has increased 
substantially.
For psychiatric services in 2008-09, a maximum of 14,323 patients had a management plan, an 
increase of 29 per cent over the previous year; and 82,524 initial consultations were billed, an 
increase of 7 per cent over the previous year. 
5Table 2: Out-patient psychiatric services: Summary of number of services and total cost.
2004-05 2005-06 2006-07 2007-08 2008-09
Items 291, 293
Management 
plans
Services 86 1,902 6,057 11,119 14,323
Cost $0.01m $0.4m $1.8m $3.7m $4.8m
Items 296, 299
Initial 
Consultations
Services - - 43,392 77,212 82,524
Cost - - $8.6m $15.6m $17.1m
Items 300-319
Consultations
Services 1,723,178 1,706,753 1,629,485 1,537,876 1,519,188
Cost $193.8m $197.7m $196.4m $194.3m $197.7m
Items 353 – 
361
Telepsychiatry
Services 202 351 646 1,081 1,336
Cost $0.02m $0.04m $0.07m $0.10m $0.14m
Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical 
Benefits Scheme
There has also been a considerable increase in Pharmaceutical Benefits Scheme (PBS) and 
Repatriation Pharmaceutical Benefits Scheme (RPBS) scripts and costs over the decade from 
financial year 1998-99 to 2008-09 (Figure 1).  Over this time, the cost of the PBS and RPBS has 
grown by 140 per cent (which equates to $4.4 billion); the number of scripts has grown by 41 
per cent.
Combining the data (using the relevant Anatomical Therapeutic Chemical (ATC) Codes) for anti-
neoplastic and immuno-modulating agents as a proxy for cancer pharmaceuticals, for the decade 
from financial year 1998-99 to 2008-09, the cost for this group of pharmaceuticals has increased 
nearly seven-fold (which equates to $1.1 billion) and script numbers have grown by 170 per cent. 
This accounts for 25 per cent of growth in PBS and RPBS costs.
The average cost per script for all pharmaceuticals (excluding cancer pharmaceuticals) has increased 
from $20.74 in 1998-99 to $31.88 in 2008-09.  For cancer drugs the average cost per script has 
increased from $225.71 to $644.21.  If PBS and RPBS had grown at same rate post 2004-05 as 
the average rate up until that time, costs would have reached $9.33 billion per year.  So on that 
basis alone, without savings from generics, the Government has saved $5.4 billion - considerably 
more than the $1.9 billion the previous Treasurer Peter Costello predicted in the 2002-03 Budget.
Perhaps more worrying, about 96 million fewer prescriptions were delivered through the PBS and 
RPBS since 2004-054 than might have been expected on the basis of annual rates of increase 
prior to that time (Figure 2).  We know little about what sort of scripts these were, but previous 
work5 suggests that one group that may have suffered were general patients taking medicines for 
mental health conditions.
While it is not within the scope of this report to analyse the likely impact of the current capacity of 
the Australian economy on the household budgets of Australian families, we can expect that there 
will be a considerable effect on the ability of many to afford needed health care.
4  PBS co-payments increased by 21 per cent in January 2005.
5  Hynd A & Russell L. Recession and depression; an analysis of the effect of co-payment increases on the use of PBS depression 
medications. February 2009. This paper was the subject of an opinion piece and a news article for the Health section of The 
Australian, 28 February 2009.
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Figure 1: Total cost of PBS and RPBS services compared with cancer-related PBS and RPBS services per 
financial year, in the years beginning June 1998-2008. 
Figure 2: Total number of scripts compared with number of cancer scripts delivered through PBS 
and RPBS per financial year, in the years beginning June 1998 – 2008.
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